Filing Flows › AbbVie (ABBV) › Q2 2026 › vs Q1 2026
AbbVie (ABBV) Q2 2026 vs Q1 2026 (quarter over quarter)
AbbVie's revenue rose $2.0B (+13%) from $15.0B in Q1 2026 to $17.0B in Q2 2026. Operating margin 37.9% against 26.6% (+11.3 pts).
AbbVie, Q2 2026: revenue $17.0B (+10% year over year), operating margin 37.9%, net earnings $3.6B, operating cash flow $3.4B. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 37.9% | 26.6% | +11.3 pts |
| Net margin | 21.3% | 4.6% | +16.6 pts |
| Free cash flow margin | 18.3% | 23.8% | -5.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $17.0B | $15.0B | $2.0B | +13% |
| Operating profit | $6.4B | $4.0B | $2.4B | +61% |
| Costs & expenses | $10.6B | $11.0B | −$454M | -4% |
| Pre-tax earnings | $4.3B | $1.0B | $3.2B | +312% |
| Other expense, net | $2.2B | $3.0B | −$797M | -27% |
| Cost of revenue | $4.3B | $4.2B | $73.0M | +2% |
| Research & development | $2.3B | $2.5B | −$128M | -5% |
| SG&A | $3.6B | $3.6B | $54.0M | +2% |
| Other operating costs | $291M | $744M | −$453M | -61% |
| Net earnings | $3.6B | $697M | $2.9B | +419% |
| Income tax | $662M | $342M | $320M | +94% |
| Depreciation & amortization | $1.9B | $1.9B | −$42.0M | -2% |
| Share-based compensation | $166M | $444M | −$278M | -63% |
| Working capital & other | $2.2B | −$752M | $3.0B | — |
| Operating cash flow | $3.4B | $3.8B | −$393M | -10% |
| Free cash flow (OCF − capex) | $3.1B | $3.6B | −$450M | -13% |
| Capital expenditures | $322M | $265M | $57.0M | +22% |
Questions
How much did AbbVie's revenue grow quarter over quarter in Q2 2026?
AbbVie's revenue rose $2.0B (+13%) from $15.0B in Q1 2026 to $17.0B in Q2 2026. Operating margin 37.9% against 26.6% (+11.3 pts).